Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA working on pattern recognition model that could ID other heparin contaminants

This article was originally published in The Gold Sheet

Executive Summary

FDA's Division of Pharmaceutical Analysis is seeking contract support to develop a multivariate mathematical model that could tell whether heparin samples contain low levels of dermatan sulfate, a common impurity, oversulfated chondroitin sulfate, an economically motivated adulterant, or other oversulfated glucosaminoglycans that the division prepares or purchases. There has been speculation that the miscreants who contaminated heparin API with OSCS might try to do it with other substances. The FDA study will use heparin nuclear magnetic resonance imaging spectra from more than 150 heparin API samples tainted with varying levels of OSCS and dermatan sulfate, plus other sample data to "determine if pattern recognition models are capable of discriminating low levels of OSCS and other contaminants in heparin sodium," FDA said

You may also be interested in...

QUOTED. 3 March 2021. Greg Dadika.

Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.

AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.

Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.

Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics

FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts